Till startsida
University of Gothenburg
Sitemap
To content Read more about how we use cookies on gu.se

Articles, Books and Chapters

2017

82. Gustafsson-Lutz A, Bäck T, Aneheim A, Palm S, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. Biotinylated and Chelated Poly-L-Lysine as Effector for Pretargeting in Cancer Therapy and Imaging. Int J Pharm Pharm Sci, 2017; 9(1):87-93

2016

81. Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S. Cure of human ovarian carcinoma solid xenografts by fractionated [211At] alpha‐radioimmunotherapy: Influence of tumor absorbed dose and effect on long‐term survival. J Nucl Med, 2016

80. Aneheim E, Gustafsson A, Albertsson P, Bäck T, Jensen H, Palm S, Svedhem S, Lindegren S. Synthesis and Evaluation of Astatinated N‑[2-(Maleimido)ethyl]-3- (trimethylstannyl)benzamide Immunoconjugates. Bioconjugate Chem, 2016; 27(3):688–697

79. Palm S, Bäck T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. J Nucl Med, 2016; 57(4):594-600

2015

78. Frost S H, Miller B W, Bäck T A, Santos E B, Hamlin D K, Knoblaugh S E, Frayo S L, Kenoyer A L, Storb R, Press O W, Wilbur D S, Pagel J M, Sandmaier B M. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation, J Nucl Med, 2015; 56(11):1766-1773

77. Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab’)2 in Intraperitoneal Therapy of Ovarian Cancer Patients, Int J Radiation Oncol Biol Phys, 2015; 93 (3):569-576

76. Aneheim E, Albertsson P, Bäck T, Jensen H, Palm S, Lindegren S.
Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials, Scientific Reports 2015;5:12025

75. Green J D, Shadman M, Jones J C, Frayo S L, Kenoyer A L, Hylarides M D, Hamlin D K, Wilbur S, Balkan E R, Lin Y, Miller B W, Frost S H L, Gopal A K, Orozco J J, Gooley T A, Laird K L, Till B G, Bäck T, Sandmaier B M, Pagel J M, Press O W. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, Blood. 2015; 125(13):2111-2119

74. Lindegren S, Andrade L N S, Bäck T, Machado C M L, Horta B B, Buchpiguel C, Moro A M, Okamoto O K, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma M C B, Chammas R, Hultborn R, Albertsson P. Binding Affinity, Specificity and comparative Biodistribution of the Parental Murine Monoclonal antibody MX35 (anti-NaPi2b) and its Humanized Version Rebmab200, PLOS ONE. 2015; DOI:10.1371/journal.pone.0126298

73. Aneheim E, Halleröd J, Albertsson P, Jensen H, Holgersson S, Lindegren S. Shelf-life of ϵ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, a precursor for 211At labeling of antibodies, Cancer Biother Radiopharm. 2015;30(1):41-45

72. Aneheim E, Foreman M, Jensen H, Lindegren S, N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides, Appl Radiat Isot. 2015;96:1–5

71. Aneheim E, Jensen H, Albertsson P, Lindegren S. Astatine-211 labeling: a study towards automatic production of astatinated antibodies, J. Radioanal. Nucl. Chem. 2015;303(1):979-983

2014

70. Eriksson S. E, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J. Sequential Radioimmunotherapy with 177Lu and 211At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. Cancer Biother Radiopharm. 2014;29(6):1-9

69. Palm S, responsible IAEA Technical officer: PET/CT Atlas on Quality Control and Image Artefacts

68. Lindegren S, Jensen H, Jacobsson L. A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination. J. Chromatogr. A. 2014;1337:128–132

67. S Palm, responsible IAEA Technical Officer: Quantitative Nuclear Medicine Imaging: Concepts, Requirements and Methods

66. Elgqvist J, Frost S, Pouget J-P, Albertsson P. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Front. Oncol. 14 Jan, 2014. doi: 10.3389/fonc.2013.00324

2013

65. Frost S H L, Santos E B, Miller B W, Bäck T A, Hamlin D K, Wilbur S, Kenoyer A L, Frayo S L, Press O W, Storb R, Sandmaier B M, Pagel J M. Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. Blood. 2013;122(21) 5139

64. Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood. 2013; 121(18): 3759-3767

63. Chouin N, Lindegren S, Frost S, Jensen H, Albertsson P, Hultborn R, Palm S, Jacobsson L, Bäck T. Ex vivo activity quantification at the cellular scale using the Alpha Camera-technique. J Nucl Med. 2013;54(8):1347-1353

62. Eriksson SE, Bäck T, Elgström E, Jensen H, Nilsson R, Lindegren S, Tennvall J. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb., EJNMMI Research 2013;3,23 doi:10.1186/2191-219X-3-23

61. Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 2013;28(2):108-114

60. Danielsson A, Claesson K, Parris TZ, Nemes S, Helou K, Elmroth K, Elgqvist J, Jensen H, Hultborn R. Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation. Int J Radiat Biol. 2013;89(4):250-258

2012

59. Choiun N, Lindegren S, Jensen H, Albertsson P, Bäck T. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy. Q J Nucl Med Mol Imaging. 2012;56:487-495

58. Magnander K and Elmroth K. Biological consequences of formation and repair of complex DNA damage. Cancer Lett. 2012;327(1-2):90-96

57. Cederkrantz E, Angenete E, Bäck T, Falk P, Haraldsson B, Ivarsson ML, Jensen H, Lindegren S, Hultborn R, Jacobsson L. Evaluation of effects on the peritoneum after intraperitoneal alpha-radioimmunotherapy with 211At. Cancer Biotherapy Radiopharm. 2012;27(6):353-364

56. Gustafsson A, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H and Lindegren S. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol. 2012;39(1):15-22

55. Elgqvist J, Lindegren S and Albertsson P. Intraperitoneal radionuclide therapy – Clinical and pre-clinical considerations. Book chapter in Ovarian Cancer - Book 2. Publisher: InTech. ISBN 978-953-307-810-6. Link to chapter (and the entire book) 

2011

54. Frost HLS, Bäck T, Choiun N, Jensen H, Hultborn R, Jacobsson L and Lindegren S. In vivo distribution of avidin-conjugated MX35 and 211At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal alpha-radioimmunotherapy. Cancer Biother Radiopharm. 2011;26(6):727-736

53. Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood. 2011;118(3):703-711

52. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, Elmroth K. RBE of alpha-particles from 211At for complex DNA damage and cell survival in relation to cell cycle position. Int J Radiat Biol. 2011;87(4):372-384

51. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part II. Curr Radiopharm. 2011;4(4):281-282

50. Palm S, Elgqvist J and Jacobsson L. Patient-specific alpha-particle dosimetry. Curr Radiopharm. 2011;4(4):329-335

49. Lindegren S and Frost S. Pretargeted radioimmunotherapy with alpha-particle emitting radionuclides. Curr Radiopharm. 2011;4(3):248-260

48. Chouin N and Bardies M. Alpha-particle microdosimetry. Curr Radiopharm. 2011;4(3):266-280

47. Olafsen T, Elgqvist J, and Wu A. Protein targeting constructs in alpha therapy. Curr Radiopharm. 2011;4(3):197-213

46. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part I. Curr Radiopharm. 2011;4(3):176

45. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, and Elmroth K. RBE of alpha-particles from At-211 for complex DNA damage and cell survival in relation to cell cycle position. Int J Radiat Biol. 2011;87:372-384

44. S Palm, responsible IAEA Technical Officer: Clinical Training of Medical Physicists Specializing in Nuclear Medicine

2010

43. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010; 116(20):4231-4239   

42. Magnander K, Hultborn R, Claesson K, and Elmroth K. Clustered DNA damage in irradiated human diploid fibroblasts: influence of chromatin organization. Radiat Res. 2010;173:272–282

41. Bäck T and Jacobsson L. The Alpha Camera: A quantitative CCD-based digital autoradiography technique for high resolution bioimaging of alpha particles ex-vivo. J Nucl Med. 2010;51:1616-1623

40. Sgouros G, Roeske J, McDevitt M, Palm S, Allen B, Fisher D, Brill A, Song H, Howell R, and Akabani G. MIRD Pamphlet No. 22: Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51;311-328 

39. Elgqvist J, Ahlberg D, Andersson H, Jensen H, Johansson BR, Kahu H, Olsson M, and Lindegren S. Intraperitoneal alpha-radioimmunotherapy of advanced ovarian cancer in nude mice using different high specific activities. World J Oncology. 2010;1:101–110

38. Elgqvist J, Johansson BR, Partheen K, and Danielsson A. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity. Anticancer Res. 2010;30:2545–2551

37. Elgqvist J, Hultborn R, Lindegren S, and Palm S. Ovarian cancer: Background and clinical perspectives. Book chapter in Targeted Radionuclide Therapy. Lippincott Williams & Wilkins, 2010, Ed. Tod Speer. Chapter 29, pages 380–396. ISBN: 978-0-7818-9693-4.

36. Elgqvist J. Astatine-211 radioimmunotherapy of ovarian cancer – Therapeutic efficay, myelotoxocity and radiation dosimetry in an animal model. Book published at Lambert Academic Publishing in 2010. ISBN: 978-3-8383-1721-2.

35. Frost S, Jensen H, and Lindegren S. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule. Cancer. 2010;116:1101–1110

34. S Palm, responsible IAEA Technical Officer: Planning a Clinical PET Centre

2009

33. Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, and Jacobsson L. Glomerular filtration rate after alpha-radioimmunotherapy with 211At- MX35-F(ab´)2: A long-term study of renal function in nude mice. Cancer Biother Radiopharm. 2009;24:649–658

32. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer. J Oncology. 2009; volume 2010, ID 394913

31. Elgqvist J, Andersson H, Haglund E, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm. 2009;24:509–513

30. Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, and Hultborn R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab´)2 – a phase I study. J Nucl Med. 2009;50:1153–1160

29. S Palm, responsible IAEA Technical Officer: Quality Assurance for PET and PET/CT Systems

28. S Palm, responsible IAEA Technical Officer: Quality Assurance for SPECT Systems

2008

27. Lindegren S, Frost S, Bäck T, Haglund E, Elgqvist J, and Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med. 2008;49:1537–1545

2007

26. Claesson K, Stenerlöw B, Jacobsson L, and Elmroth K. Relative biological effectiveness of the alpha-particle emitter 211At for double-strand break induction in human fibroblasts. Radiat Res. 2007;167:312–318

25. Palm A, Bäck T, Claesson I, Danielsson A, Elgqvist J, Frost S, Hultborn R, Jensen H, Lindegren S, and Jacobsson L. Therapeutic efficacy of astatine-211–labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69:572–579

2006

24. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006;33:1065–1072

23. Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. Int J Radiat Oncol Biol Phys. 2006;66:1228–1237

22. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342–1350

2005

21. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, and Jacobsson L. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907–1915

20. Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, and Jacobsson L. 211At Radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med. 2005;46:2061–2067

19. Elgqvist J, Bernhardt P, Hultborn R, Karlsson B, Lindegren S, Warnhammar E, and Jacobsson L. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med. 2005;46:464–471

2004

18. Palm S, Humm JL, Rundqvist R, and Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218–225.

17. Ballangrud A, Yang W, Palm S, Enmon R, Borchardt P, Pellegrini V, McDevitt M, Scheinberg D, and Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489–4497

2003

16. Palm S, Enmon R Jr, Matei C, Kolbert K, Xu S, Zanzonico P, Finn R, Koutcher J, Larson S, and Sgouros G. Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44:1148–1155

15. Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, and Palm S. Astatine-211 labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clinical Cancer Res. 2003;9:3914–3921(S)

14. Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, and Skarnemark G. At-211 labelled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-Lysine as multicarriers. Clinical Cancer Res. 2003;9:3873–3879(S)

13. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Lindegren S, and Jacobsson L. Single-cell irradiation from At-211 labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. Anticancer Res. 2003;23:1219–1222.

2002

12. Lindegren S, Andersson H, Jacobsson L, Back T, Skarnemark G, and Karlsson B. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy. Bioconjug Chem. 2002;13:502–509 

2001

11. Lindegren S, Bäck T, and Jensen H. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157–160

10. Lindegren S, Andersson H, Bäck T, Jacobsson L, Karlsson B, and Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol. 2001;28:33–39

9. Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody Mov18 in nude mice with intraperitoneally growth of human ovarian cancer. Anticancer Res. 2001;21:409–412.

8. Palm S and Jacobsson L. Dosimetrical considerations in astatine-211 radioimmunotherapy in therapeutic applications of radiopharmaceuticals. Proceedings of an international seminar held in Hyderbad, India, 18–22 January, 1999. IAEA-Tecdoc 1228. International Atomic Energy Commission, Vienna, 2001;310–319.

2000

7. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Cell growth kinetics of two human cancer cell lines irradiated with astatine-211 and gamma-radiation. Anticancer Res. 2000;20:1807–1812.

6. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. The curative and palliative potential of the monoclonal antibody Mov18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts – a long term study. Acta Oncol. 2000;39:741–745

5. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I and Lindegren S. In vitro effects of free 211At, 211At-albumin, and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines. Anticancer Res. 2000;20:1005–1012.

4. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody Mov18. Anticancer Res. 2000:20:459–462.

1999

3. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Biokinetics of the monoclonal antibodies Mov 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method of the iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol. 1999;38:323–328

1998

2. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. Anticancer Res. 1998;18:1671–1676.

1. Lindegren S, Skarnemark G, Jacobsson L, and Karlsson B. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate. Nucl Med Biol. 1998;25: 659–665

Page Manager: Emma Aneheim|Last update: 1/3/2017
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://tat.gu.se/publications/articles--books---chapters/
Utskriftsdatum: 2017-11-24